Ronit Satchi-Fainaro | Pharmacology | Outstanding Scientist Award

Published on 16/10/202418/10/2024 by Shen Awards

Prof Dr. Ronit Satchi-Fainaro | Pharmacology | Outstanding Scientist Award

Cancer Biology Research Center at Tel Aviv University, Israel

Ronit Satchi-Fainaro is a prominent figure in cancer research, currently serving as a Full Professor in the Department of Physiology and Pharmacology at Tel Aviv University and Director of the Cancer Biology Research Center. With a Ph.D. in polymer chemistry and extensive postdoctoral training at renowned institutions, her research focuses on cancer biology, tumor dormancy, and the development of targeted nanomedicines. Satchi-Fainaro has pioneered multi-modality polymer therapeutics that combine anti-angiogenic agents with chemotherapeutics, significantly advancing the field of cancer treatment. Her impressive publication record includes groundbreaking articles in Nature Medicine and Cancer Cell, and she has filed multiple patents for her innovative findings. Additionally, she has received numerous accolades for her contributions to science, including the Humboldt Foundation Bessel Research Prize. Satchi-Fainaro’s leadership in interdisciplinary research and commitment to translating scientific discoveries into clinical applications make her a leading voice in modern cancer therapeutics.

Professional Profile

Education

Ronit Satchi-Fainaro has an impressive educational background that laid the foundation for her distinguished career in pharmacology and cancer research. She earned her Bachelor of Pharmacy (B.Pharm.) degree in Pharmacology from The Hebrew University, Faculty of Medicine, School of Pharmacy, in June 1995. Following her undergraduate studies, she completed an internship in Industrial Pharmacy at Perio Products Ltd. in Jerusalem in March 1996. Satchi-Fainaro then pursued her Ph.D. at the University of London, specializing in polymer chemistry, biochemistry, and cancer nanomedicine. Her doctoral research, titled “PDEPT: Polymer Directed Enzyme Prodrug Therapy,” was completed in November 1999 under the supervision of Prof. Ruth Duncan. Subsequently, she expanded her expertise through postdoctoral fellowships at Tel Aviv University and Harvard Medical School, focusing on tumor biology, molecular biology, and protein delivery, further solidifying her status as a leader in the field of cancer research and nanomedicine.

Professional Experience

Ronit Satchi-Fainaro is a distinguished Full Professor in the Department of Physiology and Pharmacology at Tel Aviv University and serves as the Director of the Cancer Biology Research Center. With over 15 years of leadership at the university, she has spearheaded a multidisciplinary research group focused on innovative cancer therapies. Satchi-Fainaro’s expertise encompasses polymer chemistry, biochemistry, and nanomedicine, leading to the development of targeted polymer therapeutics and nano-vaccines. She has collaborated with prominent institutions, including Harvard Medical School, where she contributed to significant advances in tumor biology and angiogenesis. Her entrepreneurial spirit is evident through her co-founding of biotech companies, such as ImmuNovation, Ltd., and her active role on various scientific advisory boards. Satchi-Fainaro has garnered numerous accolades, including the Humboldt Foundation Bessel Research Prize, reflecting her substantial impact in cancer research and drug delivery systems. Her work continues to push the boundaries of personalized medicine and cancer therapeutics

Research Interests

Ronit Satchi-Fainaro’s research interests lie at the intersection of cancer biology, pharmacology, and nanomedicine. She focuses on understanding the mechanisms underlying cancer dormancy and the tumor-host interactions that facilitate metastasis. Her innovative work involves developing targeted nanomedicines that integrate anti-stromal agents with chemotherapeutics to enhance treatment efficacy while reducing toxicity. Satchi-Fainaro’s laboratory employs advanced techniques such as molecular imaging, 3D bioprinted cancer models, and personalized theranostics to investigate tumor biology and angiogenesis. She aims to identify molecular signatures that predict tumor behavior and survivorship, driving the rational design of novel therapeutic approaches. Additionally, her interdisciplinary approach combines elements of biology, chemistry, engineering, and material sciences, facilitating the development of highly selective drug delivery systems. Through her pioneering research, Satchi-Fainaro aspires to contribute to more effective cancer therapies and improve patient outcomes in the fight against cancer.

Ronit Satchi-Fainaro has received numerous prestigious awards and honors throughout her distinguished career, reflecting her significant contributions to cancer research and nanomedicine. Notable accolades include the British Council Chevening Award, the Nagai Foundation Graduate Student Award, and the Fulbright Scholarship. She was recognized as a “Person of the Year” in Medicine by Forbes Israel and included in various influential lists, such as the “50 Most Influential Women” and “40 Under 40” by prominent Israeli journals. In addition, she has received the ERC Advanced Grant, the 3D Printing Industry Award for Medical Application of the Year, and the Bessel Research Prize from the Humboldt Foundation. Her work has garnered multiple research prizes for exceptional publications at Tel Aviv University and recognition as a Fellow of the American Institute of Medical and Biological Engineers (AIMBE). These accolades highlight her impactful research and leadership in advancing innovative cancer therapies.

Conclusion

Ronit Satchi-Fainaro is a distinguished leader in cancer research, whose innovative work in nanomedicine has significantly advanced the understanding and treatment of cancer. With a robust academic background and over 15 years at Tel Aviv University, she has successfully led multidisciplinary research initiatives that tackle complex questions in tumor biology and drug delivery. Her pioneering development of multi-modality targeted nanomedicines has not only garnered numerous patents but also positioned her at the forefront of translational research. Satchi-Fainaro’s impressive publication record in high-impact journals, coupled with her numerous accolades—including the Humboldt Foundation Bessel Research Prize—underscores her contributions to science. As the Director of the Cancer Biology Research Center, she exemplifies a commitment to fostering collaboration and mentorship in the scientific community. Overall, her accomplishments and dedication to improving cancer therapies make her a highly deserving candidate for the Research for Outstanding Scientist Award.

Publication top noted

Title: interFLOW: maximum flow framework for the identification of factors mediating the signaling convergence of multiple receptors
Authors: Sheinin, R., Salomon, K., Yeini, E., Sharan, R., Madi, A.
Year: 2024
Citations: 0
Title: Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy
Authors: Longobardi, G., Moore, T.L., Conte, C., Satchi-Fainaro, R., Quaglia, F.
Year: 2024
Citations: 0
Title: Multifunctional Nanovaccine Sensitizes Breast Cancer to Immune Checkpoint Therapy
Authors: Peres, C., Matos, A.I., Carreira, B., Satchi-Fainaro, R., Florindo, H.F.
Year: 2024
Citations: 2
Title: Combining TIGIT Blockade with MDSC Inhibition Hinders Breast Cancer Bone Metastasis by Activating Antitumor Immunity
Authors: Monteran, L., Ershaid, N., Scharff, Y., Zhang, X.H.-F., Erez, N.
Year: 2024
Citations: 3
Title: The role of CCL2/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine
Authors: Pozzi, S., Satchi-Fainaro, R.
Year: 2024
Citations: 3
Title: Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker
Authors: Liubomirski, Y., Tiram, G., Scomparin, A., Shabat, D., Satchi-Fainaro, R.
Year: 2024
Citations: 3
Title: Intranasal Multiepitope PD-L1-siRNA-Based Nanovaccine: The Next-Gen COVID-19 Immunotherapy
Authors: Acúrcio, R.C., Kleiner, R., Vaskovich-Koubi, D., Florindo, H.F., Satchi-Fainaro, R.
Year: 2024
Citations: 0
Title: Polyoxazoline-Based Nanovaccine Synergizes with Tumor-Associated Macrophage Targeting and Anti-PD-1 Immunotherapy against Solid Tumors
Authors: Matos, A.I., Peres, C., Carreira, B., Satchi-Fainaro, R., Florindo, H.F.
Year: 2023
Citations: 6
Title: Deoxyhypusine hydroxylase: A novel therapeutic target differentially expressed in short-term vs long-term survivors of glioblastoma
Authors: Ofek, P., Yeini, E., Arad, G., Geiger, T., Satchi-Fainaro, R.
Year: 2023
Citations: 4
Title: Development of Chitosan Particles Loaded with siRNA for Cystatin C to Control Intracellular Drug-Resistant Mycobacterium tuberculosis
Authors: Pires, D., Mandal, M., Matos, A.I., Florindo, H.F., Anes, E.
Year: 2023
Citations: 6

Shriyansh Srivastava | Pharmacology Award | Best Researcher Award

Published on 18/03/2024 by Shen Awards

Mr. Shriyansh Srivastava | Pharmacology Award | Best Researcher Award

Assistant Professor at Pharmacology Award, Galgotias University, India

Mr. Shriyansh Srivastava is a dedicated professional with a strong academic background and diverse expertise in the field of pharmacology and clinical research. Currently pursuing a PhD at Delhi Pharmaceutical Sciences and Research University, he previously completed his M. Pharm at ISF College of Pharmacy, where he achieved a CGPA of 8.54. With a B. Pharm from Dr. A.P.J. Abdul Kalam Technical University and a 12th-grade education from CRTS Vidya Mandir, Mr. Srivastava’s academic journey demonstrates his commitment to excellence. In addition to his academic achievements, Mr. Srivastava has been serving as an Assistant Professor at Galgotias University since August 31, 2021, focusing on the pharmaceutical field. He has attended various workshops and conferences, showcasing his dedication to continuous learning and professional development. His expertise includes operating advanced laboratory equipment such as the Langendroff Apparatus, fluorescent microscope, and centrifuge. He is also skilled in animal handling, histological studies, and using MS Office applications.

Professional Profiles:

Education:

Mr. Shriyansh Srivastava is currently pursuing a PhD in Pharmacology & Clinical Research at Delhi Pharmaceutical Sciences and Research University, New Delhi, India, from 2022 to the present. He completed his M. Pharm (Pharmacology) at ISF College of Pharmacy, Moga, Punjab, India, from 2019 to 2021, with a CGPA of 8.54. His B. Pharm was completed at Dr. A.P.J. Abdul Kalam Technical University, Lucknow, Uttar Pradesh, India, from 2014 to 2018, with a percentage of 74.82%. In 2013-2014, he completed his 12th grade at CRTS Vidya Mandir, Siswa, Maharajganj, Uttar Pradesh, India, with a percentage of 86.6%.

Professional Experience:

This information describes Mr. Shriyansh Srivastava’s current professional role as an Assistant Professor at Galgotias University. It specifies that he is part of the School of Medical and Allied Sciences, specifically in the Department of Pharmacy. The details include his start date, which is August 31, 2021, indicating the duration of his employment in this position. It also mentions his focus area, highlighting that his teaching and research activities are centered around the pharmaceutical field. Overall, this information provides an overview of his current professional responsibilities and academic focus within the university setting.

Award Participated:

Mr. Shriyansh Srivastava has actively participated in various workshops and conferences to enhance his professional knowledge and skills. He attended a workshop on advanced histopathological techniques using microtome, cryostat, and tissue processor in February 2021. He also presented at the International Conference on “Unlocking Challenges Innovations and Global Opportunities in Research Amidst COVID-19 Pandemic” in December 2020. Additionally, he participated in the 59th National Pharmacy Week 2020 organized by ISF College of Pharmacy, Moga, and attended a one-day international workshop on lung injury therapy in November 2019. He also participated in the 54th IHPA National conference on safe and effective medicine in September 2019 and the 31st Annual Conference of India Pharmacy Graduates Association in April 2017, showcasing his commitment to professional development and staying updated with the latest advancements in the field.

Skills:

Mr. Shriyansh Srivastava possesses a wide range of expertise in laboratory equipment and techniques. He is proficient in operating the Langendroff Apparatus, fluorescent microscope, centrifuge, non-invasive blood pressure apparatus, Eddy’s hot plate, plethysmometer, actophotometer, student organ bath, microtome, and cryostat. He also has experience in handling animals, particularly rats, mice, and guinea pigs. Additionally, he has a strong understanding of histological studies and is skilled in using MS Office applications (Word, Excel, PowerPoint). He is well-versed in safety requirements and laboratory management, ensuring a clean and safe workplace. Furthermore, he is knowledgeable about Windows operating systems and various application software such as ChemDraw, EndNote, and BioRender.

Publications:

Unveiling the potential of proteomic and genetic signatures for precision therapeutics in lung cancer management
- Authors: S Srivastava, N Jayaswal, S Kumar, PK Sharma, T Behl, A Khalid, …
- Year: 2024
- Citations: 7
- Journal: Cellular Signalling 113, 110932
The Global Monkeypox (Mpox) outbreak: a comprehensive review
- Authors: S Srivastava, S Kumar, S Jain, A Mohanty, N Thapa, P Poudel, K Bhusal, …
- Year: 2023
- Citations: 7
- Journal: Vaccines 11 (6), 1093
Biodegradable electrospun scaffolds as an emerging tool for skin wound regeneration: A comprehensive review
- Authors: D Sharma, S Srivastava, S Kumar, PK Sharma, R Hassani, HG Dailah, …
- Year: 2023
- Citations: 6
- Journal: Pharmaceuticals 16 (2), 325
Wnt/β-catenin antagonist pyrvinium rescues high dose isoproterenol induced cardiotoxicity in rats: Biochemical and immunohistological evidences
- Authors: S Srivastava, S Yadav, G Singh, SS Bajwa
- Year: 2022
- Citations: 6
- Journal: Chemico-Biological Interactions 358, 109902
Evolution of β-catenin-independent Wnt–GSK3–mTOR signalling in regulation of energy metabolism in isoproterenol-induced cardiotoxicity model
- Authors: S Srivastava, N Bagang, S Yadav, S Rajput, D Sharma, A Dahiya, …
- Year: 2021
- Citations: 5
- Journal: Inflammation Research 70 (7), 743-747
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
- Authors: S Dhoundiyal, S Srivastava, S Kumar, G Singh, S Ashique, R Pal, …
- Year: 2024
- Citations: 3
- Journal: European Journal of Medical Research 29 (1), 26
Emergence of Marburg virus: a global perspective on fatal outbreaks and clinical challenges
- Authors: S Srivastava, D Sharma, R Rijal, S Adhikari, P Bashyal, JJ Barboza, …
- Year: 2023
- Citations: 3
- Journal: Frontiers in Microbiology 14, 1239079
Platelet‐rich plasma exhibits anti‐inflammatory effect and attenuates cardiomyocyte damage by reducing NF‐κB and enhancing VEGF expression in isoproterenol induced …
- Authors: S Yadav, S Srivastava, G Singh
- Year: 2022
- Citations: 3
- Journal: Environmental Toxicology 37 (4), 936-953
Recent Nipah virus outbreak in India: lessons and imperatives
- Authors: S Srivastava, N Deb, P Roy, V Jaiswal, S Sah, Y Pandey, …
- Year: 2023
- Citations: 1
- Journal: Therapeutic Advances in Infectious Disease 10, 20499361231208535
Significant progress in chikungunya Control: FDA approval of Ixchiq vaccine
- Authors: S Srivastava, S Kumar, P Satapathy, KH Jaaaim, AH Hermis, R Mehta, …
- Year: 2024
- Journal: Clinical Infection in Practice, 100351